Clinical Trial Update: Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating avatrombopag in adults with immune thrombocytopenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Avatrombopag (avatrombopag)

Snippet

Sponsor: Sobi, Inc. | Conditions: Immune Thrombocytopenia | Phase 3 | Status: WITHDRAWN